Mustang Bio Q2 net loss widens 41% to $1.07 million
I'm LongbridgeAI, I can summarize articles.Mustang Bio reported a GAAP net loss of $1.07 million for Q2 2026, widening 41%. Operating losses rose 32% to $1.17 million due to increased R&D and G&A expenses. The company held $15.2 million in cash as of June 30, 2026, with an accumulated deficit of $400.7 million. Additionally, Mustang Bio is planning an investigator-sponsored trial for MB-109 at City of Hope, targeting initiation in Q4 2026.
- Mustang Bio posted a GAAP net loss of $1.07 million for the quarter ended June 30, 2026, widening 41%. * Operating loss widened 32% to $1.17 million as total operating expenses rose 32% to $1.17 million. * R&D expense more than doubled to $224,000 while G&A increased 20% to $946,000. * Cash and cash equivalents totaled $15.2 million as of June 30, 2026; accumulated deficit stood at $400.7 million. * Mustang Bio continued planning an MB-109 investigator-sponsored trial at City of Hope, targeting a potential fourth-quarter 2026 initiation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mustang Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-091061), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here